LONDON, July 7, 2026, 19:01 BST
- RUA Life Sciences Plc closed up 5.91% at 20.65p, according to Google Finance. Volume for the session was 203,050 shares.
- Retail closed at 20p bid, 22p offered, with a spread of 9.5% from the midpoint.
- RUA hasn’t posted any new RNS in the past 48 hours. The most recent filing on record is the interim results from June 30.
- RUA’s Structural Heart spinout is still big compared to the group’s equity. The company reported a non-cash gain of £4.9 million tied to the deal, and expects around £750,000 a year positive impact.
RUA Life Sciences Plc (RUA:LON) climbed Tuesday, but much of the focus was on trading costs. Google Finance’s last price at 16:30 BST was 20.65p, up 5.91%. Hargreaves Lansdown showed the spread at the close with a 20p sell and 22p buy. London trading finished before the price marks; regular LSE hours on July 7 ran from 08:00 to 16:30 BST.
The spread at that quote was 2p, or 9.5% of the 21p midpoint. That tops the last-price gain listed on Google Finance. For a microcap AIM name, that gap is important—the quoted move and the price you can actually trade can end up being two different things.
| RUA close-of-day read | Latest figure |
|---|---|
| Closing price from Google Finance | 20.65p |
| Change on the day, Google Finance | +5.91% |
| High and low today | 21.92p / 20.40p |
| Bid and offer, Hargreaves Lansdown | 20p / 22p |
| Total volume | 203,050 shares |
| Google Finance average volume | 127,580 shares |
| Estimated trade value at close | £42,000 |
| FTSE AIM All-Share open and close | 776.23 / 769.18 |
No new filings triggered the move. The most recent RNS on Investegate’s RUA page was the interim results for June 30. Before that, the last entries were a June 2 holding notice, the May 22 trading update, and the May 12 note on RUA Structural Heart financing.
June 30 results still set the tone for trade. RUA said revenue rose 6.1% to £2.747 million for the six months ended March 31. Adjusted EBITDA was £76,000, gross margin hit 74.9%, and cash was £2.365 million. Income statement showed a loss before tax of £183,000 and a period loss of £203,000.
Chairman Geoff Berg said the management team has “transformed the business” into a “profitable Contract Manufacturer.” That’s key, since the share price is now moving with a company that wants to be seen less as an R&D cash-burn story and more as a small contract manufacturer holding medical-device IP. Investegate
| Valuation pressure point | Amount | Read-through |
|---|---|---|
| RUA’s market cap on AJ Bell | £12.82 mln | Core equity level |
| Cash at March 31 | £2.365 mln | That’s nearly 18% of the market cap |
| Estimated RSH deconsolidation gain | £4.9 mln | Almost 38% of market cap |
| Forecast annual gain from new RSH setup | £750,000 | Works out to 5.9% of cap |
| Possible manufacturing deals from May update | Over £5 mln/year | Roughly 1.8x H1 top line |
RUA Structural Heart is the big item on the balance sheet here. In May, RUA said RSH got £3 million from Leducq through a convertible unsecured loan and converted £4.8 million of RUA’s intercompany debt to loan stock. RUA added it would now treat RSH as an investment instead of consolidating the unit.
CEO William Brown said the move would give RUA a “strengthened balance sheet” and improve profitability. Andy Campbell, director at RUA Structural Heart, said the leaflet was designed to bring down the risk of “catastrophic failure through leaflet tearing.” David Milan, chief scientific officer at Leducq Corporation, said if the AurTex valve works it could be “life-changing” for patients with advanced rheumatic heart disease. Investegate
The risk is the operating story hasn’t settled. RUA said cash dropped by £885,000 from Sept. 30, as receivables went up. Still, the company expects cash to recover by year-end when working capital shifts back. It also said Abiss France revenue was down because one major customer had too much stock and was cutting back.
The UK indexes were mixed and didn’t account for RUA’s move. Reuters said the FTSE 100 added 0.1% at the close on Tuesday. The FTSE 250 slipped 0.5%. Sharecast data put the FTSE AIM All-Share ending at 769.18, down from its 776.23 open.
The closest check right now is contract conversion. RUA said in May that development work over the past year was up four times, and it could turn into over £5 million a year in manufacturing contracts.
